Kissei picks up Japanese rights to SpePharm's dexrazoxane
This article was originally published in Scrip
Executive Summary
Kissei Pharmaceutical has acquired development and marketing rights in its home market of Japan to SpePharm's niche oncology supportive care drug dexrazoxane.